I am a corporate strategy where a dominant monopoly buys a tiny, innovative rival not to grow, but to bury their technology forever. What am I? The answer is a "killer acquisition."

In standard A-Level economic theory—whether you are studying AQA, Edexcel, or OCR—firms merge to achieve synergies, exploit economies of scale, or expand into new geographic markets. The goal is to grow the combined business. A killer acquisition flips this entirely on its head. The incumbent monopoly buys the nascent startup specifically to shut it down, shelve its technology, and eliminate a future threat

Why would a tech giant or a major pharmaceutical company pay £1 billion for a startup that generates zero revenue?

They are not valuing the startup based on its current balance sheet. They are valuing the Net Present Value of protecting their own monopoly. If an incumbent is making £10 billion a year in monopoly profit, spending £1 billion to eliminate a disruptive competitor before it scales is simply a rational insurance policy.

Historically, this created a massive regulatory loophole. Traditional competition authorities trigger investigations based on the revenue of the target company. Because tech and biotech startups often prioritize user growth or R&D over immediate monetization, they have virtually no turnover. Consequently, these acquisitions flew completely under the regulatory radar, allowing monopolies to continuously absorb threats and permanently destroy dynamic efficiency.